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Abstract:
The catastrophic declines of three species of Critically Endangered Gyps 
vultures in South Asia were caused by unintentional poisoning by the 
non-steroidal anti-inflammatory drug (NSAID) diclofenac. Despite a ban 
on its veterinary use in 2006 (India, Nepal, Pakistan) and 2010 
(Bangladesh), residues of diclofenac have continued to be found in cattle 
carcasses and in dead wild vultures. Another NSAID, meloxicam, has 




covert surveys of pharmacies in India, Nepal and Bangladesh to 
investigate the availability and prevalence of NSAIDs for the treatment 
of livestock. The purpose of the study was to establish whether 
diclofenac continued to be sold for veterinary use, whether the 
availability of meloxicam had increased and to determine what other 
veterinary NSAIDs were available. The availability of diclofenac declined 
in all three countries, virtually disappearing from pharmacies in Nepal 
and Bangladesh, highlighting the advances made in these two countries 
to reduce this threat to vultures. In India, diclofenac still accounted for 
10-46% of all NSAIDs offered for sale for livestock treatment in 2017, 
suggesting weak enforcement of existing regulations and a continued 
high risk to vultures. Availability of meloxicam increased in all countries, 
and was the most common veterinary NSAID in Nepal (89.9% in 2017). 
Although the most widely available NSAID in India in 2017, meloxicam 
accounted for only 32% of products offered for sale. In Bangladesh, 
meloxicam was less commonly available than the vulture-toxic NSAID 
ketoprofen (28% and 66%, respectively, in 2018), despite the partial 
government ban on ketoprofen in 2016. Eleven different NSAIDs were 
recorded, several of which are known or suspected to be toxic to 
vultures. Conservation priorities should include awareness raising, 
stricter implementation of current bans, bans on other vulture-toxic 
veterinary NSAIDs, especially aceclofenac and nimesulide, and safety-
testing of other NSAIDs on Gyps vultures to identify safe and toxic 
drugs. 
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24 The catastrophic declines of three species of Critically Endangered Gyps vultures in South Asia were 
25 caused by unintentional poisoning by the non-steroidal anti-inflammatory drug (NSAID) diclofenac. 
26 Despite a ban on its veterinary use in 2006 (India, Nepal, Pakistan) and 2010 (Bangladesh), residues 
27 of diclofenac have continued to be found in cattle carcasses and in dead wild vultures. Another 
28 NSAID, meloxicam, has been shown to be safe to vultures. From 2012 to 2018, we undertook covert 
29 surveys of pharmacies in India, Nepal and Bangladesh to investigate the availability and prevalence 
30 of NSAIDs for the treatment of livestock. The purpose of the study was to establish whether 
31 diclofenac continued to be sold for veterinary use, whether the availability of meloxicam had 
32 increased and to determine what other veterinary NSAIDs were available. The availability of 
33 diclofenac declined in all three countries, virtually disappearing from pharmacies in Nepal and 
34 Bangladesh, highlighting the advances made in these two countries to reduce this threat to vultures. 
35 In India, diclofenac still accounted for 10-46% of all NSAIDs offered for sale for livestock treatment in 
36 2017, suggesting weak enforcement of existing regulations and a continued high risk to vultures. 
37 Availability of meloxicam increased in all countries, and was the most common veterinary NSAID in 
38 Nepal (89.9% in 2017). Although the most widely available NSAID in India in 2017, meloxicam 
39 accounted for only 32% of products offered for sale. In Bangladesh, meloxicam was less commonly 
40 available than the vulture-toxic NSAID ketoprofen (28% and 66%, respectively, in 2018), despite the 
41 partial government ban on ketoprofen in 2016. Eleven different NSAIDs were recorded, several of 
42 which are known or suspected to be toxic to vultures. Conservation priorities should include 
43 awareness raising, stricter implementation of current bans, bans on other vulture-toxic veterinary 
44 NSAIDs, especially aceclofenac and nimesulide, and safety-testing of other NSAIDs on Gyps vultures 
45 to identify safe and toxic drugs. 
46







49 The non-steroidal anti-inflammatory drug (NSAID) diclofenac is nephrotoxic to Gyps vultures (Oaks et 
50 al. 2004, Swan et al. 2006a). The widespread use of diclofenac in South Asia during the 1990s and 
51 2000s to provide palliative care to dying cattle caused catastrophic declines in populations of the 
52 three resident Gyps vulture species endemic to the region, White-rumped G. bengalensis, Indian G. 
53 indicus and Slender-billed G. tenuirostris Vultures. Vultures were exposed to sufficient levels of 
54 contaminated food to cause the observed population declines when they fed upon carcasses of 
55 cattle which had been treated with diclofenac shortly before their death (Green et al. 2004, 2007). 
56 To save vultures from extinction, the Governments of India, Nepal and Pakistan banned the 
57 manufacture of veterinary formulations of diclofenac in 2006, followed by the Government of 
58 Bangladesh in 2010. 
59
60 In India, repeated road transect surveys of vultures across much of their former range have shown at 
61 least a slowing of declines since the ban and a possible partial recovery in the population of White-
62 rumped Vulture (Prakash et al. 2017). In addition, both the prevalence and concentration of 
63 diclofenac in cattle carcasses sampled throughout the same area declined between 2006 and 2009 
64 such that the estimated vulture death rate per meal decreased by about two-thirds (Cuthbert et al. 
65 2014). However, up to that time, the ban had not eliminated diclofenac from vulture food in India or 
66 allowed vulture populations to recover strongly. Furthermore, the proportion of vultures found dead 
67 in the wild in India with diclofenac residues showed only a slight and non-significant decline after the 
68 ban (Cuthbert et al. 2016). 
69
70 Cuthbert et al. (2011) surveyed pharmacies selling veterinary drugs in India and found that many 
71 were stocking and selling human formulations of diclofenac for illegal use in cattle. This misuse was 





72 made more practical by the manufacture and distribution to veterinary pharmacies, by some Indian 
73 pharmaceutical companies, of human formulations of diclofenac in large vials containing enough of 
74 the drug to dose cattle. This explained why many cattle carcasses were still found with diclofenac 
75 residues (Cuthbert et al. 2014), dead vultures were still found with diclofenac residues and visceral 
76 gout (Cuthbert et al. 2015), and vulture populations had not recovered strongly (Prakash et al. 
77 2017). The prevalence of diclofenac in cattle carcasses before and after bans in Bangladesh, Nepal 
78 and Pakistan was not measured. However, population surveys of vultures in Nepal and Pakistan have 
79 shown a reversal of declines since the bans on veterinary diclofenac (Chaudhry et al. 2012, Galligan 
80 et al. 2019).
81
82 In 2015, the Government of India strengthened its regulations on diclofenac by banning the 
83 manufacture of human formulations in vials larger than a single human dose (3 ml). Two Indian 
84 pharmaceutical companies immediately challenged the ban, but it was upheld in the High Court of 
85 Madras in 2017. This strengthening of the ban may make diclofenac use in cattle less practical and 
86 expensive, because multiple small vials would need to be used, and further reduce the illegal use of 
87 human diclofenac formulations in cattle in India, though the legal challenge to the ban on the use of 
88 larger vials would have delayed this effect. Given the influence of India’s pharmaceutical industry in 
89 the region and the far-ranging movements of vultures, this enhancement of the ban is expected to 
90 have a positive effect on vultures in neighbouring countries as well. 
91
92 Another NSAID, meloxicam, is the only veterinary NSAID known not to be toxic to Gyps vultures at 
93 doses likely to be used in veterinary practice (Swan et al. 2006b). Conservationists and governments 
94 in South Asia have been promoting the use of meloxicam while discouraging the use of diclofenac. In 
95 India, the prevalence of meloxicam in cattle carcasses increased by nearly half between 2006 and 
96 2009, whilst the prevalence of diclofenac decreased (Cuthbert et al. 2014a).  In addition, the 
97 prevalence of diclofenac in cattle carcasses in India decreased most in regions where meloxicam 





98 prevalence increased most (Cuthbert et al. 2014b). Counteracting this positive trend, there are many 
99 other NSAIDs available for use on cattle in South Asia, including aceclofenac, which metabolises into 
100 diclofenac in cattle (Galligan et al. 2016), ketoprofen and carprofen which are toxic to Gyps vultures 
101 (Naidoo et al. 2010, 2018), and nimesulide and flunixin, which have been found in dead wild Gyps 
102 vultures with visceral gout and are therefore probably vulture-toxic (Zorrilla et al. 2014, Cuthbert et 
103 al. 2015). 
104
105 In this study, we undertook covert (undercover) surveys of pharmacies selling veterinary drugs in 
106 India, Nepal and Bangladesh to determine which NSAIDs are being sold for use in cattle. The use of 
107 covert surveys was necessary as the sale of diclofenac for veterinary purposes is illegal in all three 
108 countries and availability would otherwise have been significantly under-reported from overt 
109 surveys (Cuthbert et al. 2011). Our aims were to assess (1) how effective the ban on veterinary 
110 diclofenac has been, (2) whether the only known vulture-safe drug, meloxicam, has taken over from 
111 diclofenac as a preferred drug, and (3) what other NSAIDs are currently available. 
112
113 Methods
114 Repeated covert surveys of pharmacies were carried out in eight regions of India, three regions of 
115 Nepal, and three regions in Bangladesh. Whereas the same regions were consistently surveyed in 
116 India and Nepal, the first survey in Bangladesh covered the whole country, while the second and 
117 third surveys were conducted in the country’s two provisional Vulture Safe Zones (pVSZ) centred on 
118 the Sylhet and Khulna Divisions (administrative regions). The latter two surveys in Bangladesh, 
119 therefore, constituted repeat coverage of the same regions. The survey was based upon sampling of 
120 settlements, which were towns, villages or clusters of small villages. Settlements were selected at 
121 random within each region. Data were collected from just one pharmacy in each settlement visited, 
122 thus avoiding possible pseudoreplication arising from likely patterns among pharmacies within 





123 settlements. The name, address and sometimes the geographical coordinates of each pharmacy was 
124 recorded by the survey team from the vehicle on the first survey and used to locate the same 
125 pharmacy in future years. In India and Bangladesh, surveyors were employees of the organisations 
126 undertaking the surveys (BNHS and IUCN Bangladesh, respectively), whereas in Nepal, a local man 
127 was paid to visit a pharmacy and purchase medicine for an injured cow.
128 Methods varied between countries. In India, a member of the survey team asked the pharmacist for 
129 “a painkiller for an injured cow”. However, in surveys in 2012 and 2013 in Jharkhand, Uttarakhand 
130 and Uttar Pradesh, surveyors specifically asked for, or a had a prescription, for diclofenac. Diclofenac 
131 was offered more frequently when the drug was specifically requested (44.2% of pharmacies), 
132 compared to when the standard method was followed (15.6%, χ21 = 42.38, P < 0.0001). Therefore, 
133 surveys that did not follow the standard method have been excluded from the modelling of trends 
134 over time. In Nepal, a prescription written by a veterinarian for one 30 ml vial of diclofenac and five 
135 tablets of deworming medication was presented to the pharmacist. In both India and Nepal, the first 
136 drug offered by the pharmacist was bought, regardless of what had been requested, although it was 
137 often the case that no drug was offered, because the pharmacist either did not stock, or had run out 
138 of, this type of drug. In Nepal, drugs intended for animals and humans are often sold in separate 
139 shops; therefore, surveys were conducted in both ‘Animal’ and ‘Human’ pharmacies, but it was 
140 always made clear that the drug purchased was intended for use on cattle. In Bangladesh, surveyors 
141 asked to see all NSAIDs in stock in each pharmacy. Data were collected from the packaging of the 
142 purchased (and in Bangladesh, stocked) drugs, including brand name, name and concentration of the 
143 active ingredient(s), vial size and the manufacturer’s name and address. 
144
145 Statistical analysis
146 Changes over time in the first NSAID offered for sale in India and Nepal were tested by fitting logistic 
147 regression models. Whether or not an NSAID was the first drug offered and subsequently bought 





148 during a pharmacy visit was the binary dependent variable with binomial error and a log link 
149 function, and was modelled in relation to the calendar year as a continuous variable. The same 
150 modelling approach was used to study trends in the availability of individual NSAIDs, but only 
151 including data from pharmacy visits in which an NSAID of some kind was offered. Interaction terms 
152 between regions and year were not fitted and data for each region of India and Nepal were 
153 modelled separately. After inspecting the data, we included the quadratic effect of calendar year 
154 when modelling trends in sales of meloxicam in the Western Terai region of Nepal. We report the 
155 slope of the fitted logistic regression (b) from these analyses and tested the statistical significance of 
156 its difference from zero using its asymptotic standard error and a t-test. This coefficient represents 
157 the modelled mean change per year in the logarithm of the odds of a drug being offered under a 
158 model in which the log odds is assumed to be a linear function of year.  Negative b values indicate 
159 declines over time and positive values represent increases. Where data were only available from two 
160 surveys, i.e. the repeat survey of the two pVSZs in Bangladesh, we performed chi-square tests of 
161 association to investigate differences between surveys in the relative proportions of selected NSAIDs 
162 (proportion of all NSAIDs stocked that were meloxicam versus ketoprofen). The proportion of 
163 diclofenac offered in vials of different sizes before and after the ban on vials > 3 ml was also 
164 investigated with a chi-squared test of association. 
165 Human ethics
166 This study involved interactions with people, including staff of pharmacies and the local men 
167 recruited to collect data. The welfare of these participants was considered. Pharmacy staff were 
168 approached in their shops, open to the public, therefore, our interactions occurred in the public 
169 sphere, where a person accepts the responsibility of their actions and those actions can be publicly 
170 observed (Spicker 2011).  Thus, pharmacy staff waive the rights normally given to participants in 
171 research (e.g. consent, withdraw, privacy; Spicker 2011), permitting covert interactions.  Deceit to 
172 elicit a sale of diclofenac (i.e. asking for a painkiller for an animal and using a mock prescription) was 





173 needed to uncover illegal behaviour.  Covert interactions and deceit are important tools for data 
174 collection in conservation science, particularly when investigating illegal behaviour.  Both are 
175 justified because obtaining accurate data would otherwise not be possible.  Further, illegal 
176 behaviour is a concern of the public and public rights take priority over individual rights in such 
177 circumstances (Spicker 2011).  In this case, the conservation of vultures and the ecosystem services 
178 that they provide are concerns of the public, and the sale of diclofenac and the killing of vultures in 
179 Bangladesh, India and Nepal are crimes and thereby concerns of the public.  
180
181 In India and Bangladesh, surveyors were members of conservation organisations managing the 
182 surveys and, therefore, understood the reasons behind the surveys. In Nepal, where local men were 
183 asked to collect data, they were given full information regarding the purpose of the survey. Thus, 
184 fully appraised, they were able to make an informed decision whether to participate or not, and 
185 were also given the right to withdraw at any time. No data were collected on the local men. 
186
187 Our study was sanctioned by state and national agencies responsible for wildlife protection and drug 
188 control through the respective countries’ Government-endorsed Vulture Conservation Action Plans. 
189 A summary of our data was sent to the relevant authorities, although offending individuals were not 
190 reported, and are not identified in this paper.   




195 A total of 1452 covert pharmacy visits were made in all regions of India between 2012 and 2017, 
196 during which an NSAID was bought on 1129 (77.8%). No drug was offered on 15.0% of all visits (N = 
197 217).  Of these cases, pharmacy staff refused to sell any drug on 35 of visits, most often (N = 25) 
198 because a prescription was not provided. An alternative drug, rather than an NSAID, was offered on 





199 7.3% of visits (N = 106) and this was usually an antibiotic (N = 70). The proportion of pharmacies in 
200 which an NSAID was bought varied between regions (range, 54% (Central Gujarat) to 98% (Haryana 
201 pVSZ)) and declined significantly over the course of the study (effect of year, b = -0.392 ± 0.05, t = 
202 8.34, P < 0.0001). Of those pharmacies that did not offer any NSAID, 119 (37%) offered another type 
203 of drug. Where the data were recorded (n = 1108 visits), 78% of all NSAIDs were sold in injectable 
204 form, rather than a bolus, but the proportion of injectable forms was higher for diclofenac (97%). 
205
206 Meloxicam, diclofenac, nimesulide and piroxicam accounted for the majority of NSAIDs sold (93%), 
207 the remainder consisting of six other drugs: aceclofenac, metamizole (tradename Analgin), 
208 ketoprofen, mefenamic acid, phenylbutazone and tolfenamic acid (Table 1). In those regions in 
209 which surveyors asked explicitly for diclofenac (Jharkhand, Uttarakhand and Uttar Pradesh), there 
210 was a significant reduction in the proportion of NSAIDs sold that were diclofenac between 2012 
211 (53.8%) and 2013 (14%, χ21 = 22.79, P < 0.0001). Excluding those region/year combinations in which 
212 the standard survey method was not used (see Methods), there were significant declines in the 
213 proportion of visits at which diclofenac was offered in both Assam and Madhya Pradesh, but there 
214 was a significant increase in southern Gujarat (Fig. 1a, Table 2). Diclofenac was bought in all five 
215 regions during the final survey in 2017 (10-46% of all NSAIDs sold). Across all surveys in India, only in 
216 Assam in 2016 was diclofenac not offered for sale, from a high of 30% of NSAIDs bought in 2012 
217 (Table 1). Diclofenac was either the most frequent or joint most frequently offered drug in both 
218 regions of Gujarat in 2017; and reached 20% of sales in Madhya Pradesh and Uttar Pradesh. 
219 Diclofenac was sold in various vial sizes (1, 2, 3, 9, 15, 30 and 50 ml) and manufactured in India (46 
220 companies overall, 15 companies in 2017). In 2012-2015, before the ban in 2016 on the production 
221 of large vials (> 3 ml) of diclofenac for human medicine, 92% (n = 224) of vials sold were > 3 ml, but 
222 this proportion significantly dropped to 54% (n = 76) after the ban (2016-2017; χ21 = 53.80, P < 
223 0.0001). Of those large vials sold after the government ban on large vials (n = 41), four (10%) had a 
224 manufacturing date that post-dated the ban, the rest consisted of older stock. Commented [JM1]:  TABLE 1; FIGURE 1A






226 Meloxicam was the most commonly offered drug overall (36% of NSAIDs bought). There were 
227 significant increases in the proportion of visits where this drug was offered in Madhya Pradesh and 
228 Uttar Pradesh, but little evidence of change in Assam, Central Gujarat and Southern Gujarat (Table 2; 
229 Fig. 1b). In 2017, meloxicam constituted 15-46% of sales in the five regions surveyed using the 
230 standard method although it was more prevalent in other regions earlier in the study (Table 1). It 
231 accounted for the highest (or joint highest) sales in Southern Gujarat, Madhya Pradesh and Uttar 
232 Pradesh in 2017. There were near- significant increases in the proportion of visits where nimesulide 
233 was offered in Madhya Pradesh and Assam (Table 2; Fig. 1c). Nimesulide had the second-highest 
234 sales in the Haryana pVSZ (37%) in 2017. Including only those regions where the drug was prevalent 
235 (Madhya Pradesh and Uttar Pradesh), sales of piroxicam remained stable (Table 2). In 2017, 
236 piroxicam was the most frequently bought drug in Madhya Pradesh (30%), and the second most 
237 frequently bought drug in Uttar Pradesh (25%). 
238
239 Nepal
240 A total of 774 covert visits to ‘Animal’ pharmacies were made between 2012 and 2017, during which 
241 an NSAID was bought at 594 (76.7%), the proportion declining over the course of the study (year, b = 
242 -0.211 ± 0.04, t = 5.00, P < 0.0001). In all cases where an ‘Animal’ pharmacy did not sell an NSAID, no 
243 other drug was offered. Where the data were recorded (n = 593), 95% of NSAIDs were sold in 
244 injectable form, rather than a bolus. 
245
246 Meloxicam was by far the most prevalent NSAID bought in ‘Animal’ pharmacies (92.9% of NSAIDs, n 
247 = 594), with five other drugs being sold in a few pharmacies (Table 3). The trend in the proportion of 
248 meloxicam bought varied between regions (Table 3). In the Western Terai, after an initial increase, 
249 there was evidence of a decline in the final survey in 2016 (Table 4; Fig. 2a). Sales of diclofenac, 
250 relative to all NSAIDs, were low in all surveys (n = 8/594, 1.3%), and the drug completely disappeared 
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251 from pharmacies in two regions (Fig. 2b). On all eight occasions when diclofenac was bought, it was 
252 of human formulations in large (30 ml) vials, and occurred both before and after the ban by the 
253 Government of India on the production of large vials. Those bought in the latest surveys (2017; n = 
254 2) were manufactured in March 2015. Nimesulide was bought with increasing frequency across the 
255 course of the study (Table 4), with a particularly sharp rise in the Western Terai (b = 1.437 ± 0.54, t = 
256 2.65, P = 0.008; Fig. 2c). 
257
258 A total of 672 covert visits were made to ‘Human’ pharmacies, during which an NSAID was bought 
259 for use on cattle on only 30 (4.5%) occasions. The drug bought was almost always diclofenac and was 
260 sold in 3 ml (n = 25) and 30 ml vials (n = 5). Sales of diclofenac in ‘Human’ pharmacies significantly 
261 declined from 18/80 (22.5%) in 2013 to 1/184 (0.5%) in 2017 (χ21 = 37.03, P < 0.0001). The non-
262 NSAID paracetamol (acetaminophen) was also offered during two visits. 
263
264 Bangladesh
265 Covert visits were made to a total of 215 pharmacies in the first survey, in 102 (47%) of which 
266 NSAIDs were available to buy for veterinary use. In the second and third surveys, 128 (Sylhet, n = 66; 
267 Khulna, n = 62) and 129 (Sylhet, n = 71; Khulna, n = 58) pharmacies were visited, in which NSAIDs 
268 were available in 97%. The absolute number of NSAID products stocked by pharmacies was 1095 
269 (first survey = 340, second survey = 374 and third survey = 381; Table 5). In those pharmacies 
270 stocking NSAIDs, the maximum number of different drugs was six, although most carried just one or 
271 two. Where the data were recorded (n = 1091), 84% of NSAIDs were available in injectable, rather 
272 than bolus, form (82-100% in different regions).
273
274 Combining all regions and surveys, of the 1,095 NSAID products stocked, the majority were either 
275 ketoprofen or meloxicam (94%; Table 5). Across the two repeat surveys in the Sylhet and Khulna 
276 pVSZs, there was a significant decline in the proportion of ketoprofen available (Fig. 3a) relative to 
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277 meloxicam (Fig. 3b; χ21 = 4.88, P = 0.027). The availability of other NSAIDs was low in all surveys, 
278 including diclofenac, stocks of which declined to zero in the final survey (Table 5; Fig.3c).
279
280 Diclofenac was available in only two large vial sizes (30 and 50 ml) and was manufactured by 
281 companies in Bangladesh and India. Where it was recorded (n = 1078), 59% of all NSAIDs were 




286 The effect of differences in survey methods
287 Different methods were used in each of the countries surveyed. In India surveyors asked for a 
288 painkiller for their injured cow, in Nepal a prescription for diclofenac was presented to the 
289 pharmacist and in Bangladesh surveyors asked to see all NSAIDs stocked. These differences make 
290 comparisons between countries of the absolute levels of availability of drugs invalid. Asking for a 
291 specific drug is likely to increase the frequency with which that drug is offered by a pharmacist. 
292 However, the same method was used for surveys within each region and country, so we maintain 
293 that comparisons within regions and countries of trends over time are valid. Notwithstanding the 
294 above, in those countries (Nepal and Bangladesh) where diclofenac was specifically asked for, by the 
295 end of the survey period availability of this drug was very low. This suggests that we are justified in 
296 concluding that conservation organisations and government authorities in Nepal and Bangladesh 
297 have had greater success in removing veterinary diclofenac from pharmacies than they have in India.
298
299 Sales of the vulture-toxic NSAID diclofenac declined across all three countries surveyed, but the 
300 extent varied markedly, the drug all but disappearing from Nepal and Bangladesh, but remaining 
301 common in most regions of India. In contrast, the availability of the vulture-safe drug meloxicam 
302 increased, or remained high, across many regions, especially in Nepal. However, other NSAIDs, some 
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303 of them known or suspected to be toxic to vultures, remained prevalent, especially ketoprofen in 
304 Bangladesh. 
305
306 The decline in diclofenac
307
308 Although the governments of India, Nepal and Pakistan banned the veterinary use of diclofenac in 
309 2006 and Bangladesh did so in 2010, our data reveal that the ban did not eliminate sales of the drug 
310 in India. By the start of our surveys (2012), six years after the ban, diclofenac still accounted for the 
311 largest share (44%) of NSAIDs offered for sale in India. However, our data suggest that the 
312 strengthening of the ban to include all large (> 30 ml) vials of diclofenac may have been partially 
313 successful in reducing its prevalence in favour of other drugs. Over half the diclofenac bought after 
314 the strengthening of the ban was in large vials, and most of these consisted of old stock, 
315 manufactured before the ban. Notably, the large vials manufactured after 2015 were all illegally 
316 manufactured by Indian pharmaceutical companies. 
317
318 The proportion of diclofenac sold in India declined over the period covered by our surveys. This may 
319 be attributable to awareness-raising programmes that occurred alongside our surveys, which 
320 included meetings with veterinarians, pharmacists, livestock owners and veterinary and pharmacy 
321 associations. Variation in the implementation of such advocacy may be part of the reason for the 
322 variation in trends in diclofenac sales between regions. For instance, in Assam, diclofenac sales 
323 dropped to zero after five annual surveys; whereas, in Gujarat (Central and Southern), after a decline 
324 between 2012 and 2013, sales increased again by the time of the next survey and awareness-raising 
325 programme in 2017. Thus, awareness-raising needs to be continued if it is to be effective. 
326
327 The slow and incomplete reduction in diclofenac availability in veterinary pharmacies is the probable 
328 cause of the decline in the prevalence and concentration of diclofenac in cattle carcasses since 2006 





329 (Cuthbert et al. 2014a). These changes may be starting to have an impact on vulture populations, 
330 with the declines in White-rumped Gyps bengalensis, Indian G. indicus and Slender-billed Vultures G. 
331 tenuirostris in India having slowed since the ban on diclofenac (Prakash et al. 2017). 
332
333 In contrast to the situation in India, diclofenac virtually disappeared from pharmacies in both Nepal 
334 and Bangladesh. This may have been due to effective advocacy and education, as well as strong 
335 government support, especially in promoting meloxicam in Nepal. However, the fact that most 
336 diclofenac is manufactured by Indian companies may contribute significantly. The one Nepali 
337 company found to be manufacturing 30 ml vials of diclofenac for human use during the first ‘Human’ 
338 pharmacy survey, voluntarily stopped after being asked to do so by conservationists. Diclofenac 
339 could still find its way into cattle via importation across the long, permeable borders with India, 
340 where it is more easily obtainable (K. Paudel, unpublished information), although the rapid partial 
341 recovery of White-rumped Vulture populations in Nepal since 2013 (Galligan et al. 2019) suggests 
342 that this is not happening on a large scale.  Meanwhile, the recent strengthening of the ban in India 
343 will also reduce the risk of diclofenac imports and benefit vultures in Nepal and Bangladesh.
344
345 The rise of meloxicam
346
347 Sales of meloxicam increased in some of the regions we surveyed, and was the most common drug 
348 sold in pharmacies in Nepal. In India and Bangladesh, although availability increased in some regions, 
349 meloxicam was rarely the most common NSAID sold. Meloxicam is the only NSAID that has been 
350 shown through safety testing (Swan et al. 2006b; Swarup et al. 2007) to be non-toxic to Gyps 
351 vultures at doses they are likely to be exposed to in the wild. It has therefore been promoted to 
352 pharmacists and cattle-owners by conservationists across South Asia. Such advocacy has been 
353 particularly successful in Nepal. This has been aided by national and local government bodies 
354 promoting meloxicam after the ban on veterinary diclofenac in 2006, and later instigating a 





355 diclofenac-for-meloxicam exchange programme in 2010. Similar advocacy in Bangladesh, including 
356 distributing meloxicam to pharmacists and veterinarians free of charge, has helped this drug to 
357 maintain its market share, although it lags well behind ketoprofen. 
358
359 Meloxicam is an effective painkiller. In a review of experimental and clinical studies, 79% of 117 
360 studies reported positive effects of the drug on domesticated animals (SAVE 2016). However, many 
361 formulations of meloxicam are disliked by users because they cause the animal pain when injected, 
362 which is associated with the high pH and high osmolarity of meloxicam formulations produced in 
363 India (Cuthbert et al. 2014b), which are higher than that of the original formulation produced in 
364 Europe. Subsequently, a number of regional pharmaceutical companies have been able to replicate 
365 the original meloxicam formulation after the developer relaxed its patent (C. Bowden, unpublished 
366 information). 
367
368 The appearance of new NSAIDs
369
370 Several other NSAIDs are widely available, some of which are known to be toxic to vultures, the most 
371 prevalent being nimesulide and ketoprofen. With the decline of the once-ubiquitous diclofenac, 
372 there are now gaps in the market that pharmaceutical companies are keen to fill with alternatives. 
373 For instance, in Nepal, one company promoted its nimesulide product by distributing it without 
374 charge (K. Bhusal, unpublished information). 
375
376 In a nationwide study of dead vultures in India, post-mortem analysis revealed nimesulide residues 
377 in five (of 62) dead vultures, four of which had extensive visceral gout, a symptom of NSAID toxicity 
378 formerly only associated with high diclofenac residues (Cuthbert et al. 2016). Confirming that 
379 nimesulide is indeed toxic to Gyps vultures, two captive Cape Griffon Vultures G. coprotheres that 





380 were unable to be released due to injury were dosed (by oral gavage) with nimesulide during safety 
381 testing, and died displaying symptoms of NSAID toxicity (Galligan et al. in prep.). 
382
383 Ketoprofen has been shown in safety tests on captive birds to be nephrotoxic to vultures (Naidoo et 
384 al. 2010). Although the drug has not yet been found in carcasses of wild vultures, lethal 
385 concentrations have been found in cattle carcasses in India (Taggart et al. 2009). Following advocacy 
386 by conservationists, the Government of Bangladesh banned veterinary use of ketoprofen in the two 
387 pVSZs in 2016, but this appears to have been only partially successful in reducing the drug’s 
388 availability, despite an intensive awareness-raising campaign and promotion of meloxicam. One 
389 reason for its apparent resilience in the market may be the unfounded rumour that ketoprofen is 
390 safe to use on pregnant animals while meloxicam is not, which is not substantiated by published 
391 experimental and clinical studies, none of which even examined ketoprofen and pregnancy (SAVE 
392 2016). Conversations with pharmacy owners during the third survey revealed that they were almost 
393 all aware of the ban on ketoprofen and that some were selling stocks acquired before the ban 
394 (A.B.M.S. Alam, unpublished information). 
395
396 Other NSAIDs were available, usually at low prevalence, but including several known or suspected to 
397 be toxic to vultures, such as aceclofenac and flunixin. Aceclofenac is structurally very similar to 
398 diclofenac and is metabolised to the latter in various species of mammal, including cattle (Sharma 
399 2012; Galligan et al. 2016); therefore, aceclofenac is expected to have the same effect on vultures as 
400 diclofenac (Galligan et al. 2016). Although almost always sold in bolus form in our survey, injectable 
401 aceclofenac has recently been approved by the Indian government (C. Bowden, unpublished 
402 information). Several formulations are already available, so it could become a more popular 
403 veterinary drug in the future.  Given the high levels of diclofenac that are formed in cattle tissues 
404 soon after injection of aceclofenac (Galligan et al. 2016), any future increase in sales of aceclofenac 
405 is expected to have devastating effects on the remaining populations of vultures. 






407 Elevated flunixin residues, along with severe visceral gout, have been found in the carcasses of 
408 Eurasian Griffon Vultures Gyps fulvus in Spain (Zorrilla et al. 2014, R. Mateo, Pers. Comm.), the first 
409 reported instances of NSAID poisoning in wild vultures outside of South Asia. Flunixin was also 
410 responsible for the death of two captive Rüppell’s Vultures G. rueppellii and one captive African 
411 White-backed Vulture G. africanus at a zoo in Rome, Italy (Eleni et al. 2019). 
412
413 More encouraging was the increasing presence of tolfenamic acid, especially in Nepal and 
414 Bangladesh. Initial safety testing of this drug on Gyps vultures suggests that it may be non-toxic to 
415 vultures (Sharma et al. in prep). This would provide veterinarians and farmers with an additional 
416 vulture-safe drug, alongside meloxicam. One other drug, piroxicam, was also commonly available in 
417 Madhya Pradesh and Uttar Pradesh in the last surveys in 2017, but little is known about its toxicity 




422 The biggest threat to vultures continues to be the wide availability of diclofenac, despite having been 
423 banned by governments across South Asia. There is a clear need for greater implementation of these 
424 bans, especially in India. Similarly, the ban on ketoprofen in pVSZs in Bangladesh needs to be 
425 extended throughout this (as proposed by the Government of Bangladesh in the Bangladesh Vulture 
426 Conservation Plan (2016-2025)) and other vulture range countries. There should also be bans on the 
427 veterinary use of aceclofenac and nimesulide, which have growing market shares. 
428
429 Although awareness-raising has had some success, actions directed at pharmaceutical companies 
430 themselves may have a greater impact. This may particularly be the case in Bangladesh, where only a 
431 small number of companies manufacture ketoprofen. These companies also produce meloxicam and 





432 tolfenamic acid, so their share of the drug market may not necessarily be adversely affected if they 
433 stop ketoprofen production. 
434
435 A total of eleven different NSAIDs were recorded in this study, yet the results of safety testing have 
436 only been published for three of these drugs (diclofenac, meloxicam and ketoprofen). Such testing 
437 has been solely funded by conservation non-governmental agencies and academic sources, rather 
438 than governments or pharmaceutical companies within vulture-range countries. There is an urgent 
439 need to test these other drugs for toxicity to vultures experimentally, especially as other evidence of 
440 toxicity already exists for some of them, e.g. flunixin and nimesulide. Currently, meloxicam is the 
441 only NSAID that has been established as vulture-safe. Further safety testing of NSAIDS to identify 
442 other vulture-safe drugs, would give more choice to veterinarians and cattle-owners. Although 
443 meloxicam is known to be safe, in this survey up to half of products of this drug also contained 
444 paracetamol (India, 35%; Nepal, 43%; Bangladesh, 51%), for which there is no information regarding 
445 its safety to vultures, so the toxicity of this common painkiller also needs to be assessed.  New 
446 veterinary NSAIDs should be tested for toxicity to vultures prior to their receiving government 
447 approval through the region.  However, even more important than safety testing is that 
448 governments take action when the results from safety tests are available. Except for the ban on 
449 ketoprofen in the Bangladesh pVSZs, governments have not taken such action for other NSAIDs 
450 known to be toxic to vultures, such as aceclofenac or ketoprofen.  Given that most veterinary NSAIDs 
451 used in South Asia are manufactured in India, this is an action which should be considered by the 
452 Indian government as part of their National Action Plan for Vulture Conservation (2019-2024) and 
453 their role in the Regional Declaration on the Conservation of South Asia’s Critically Endangered 
454 Vulture Species (Anon 2012), which commits signatories to identifying and preventing the veterinary 
455 use of all vulture-toxic NSAIDs. 
456
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Table 1. The percentage of pharmacies that offered for sale the four most common NSAIDs for use in cattle, during covert (undercover) surveys in various regions of India 
in 2012-2017. N = the number of pharmacies that offered an NSAID.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Year Year
Region NSAID 2012 2013 2014 2015 2016 2017 Region NSAID 2012*** 2013*** 2014 2015 2016 2017
N 40 38 41 34 17 N 35 34
Assam Diclofenac 30.0 5.3 9.8 14.7 0.0 Jharkhand Diclofenac 54.3 14.7
Meloxicam 57.5 92.1 75.6 70.6 76.5 Meloxicam 34.3 61.8
Nimesulide 5.0 2.6 9.8 2.9 23.5 Nimesulide 2.9 0.0
Piroxicam 0.0 0.0 0.0 0.0 0.0 Piroxicam 0.0 0.0
Other** 7.5 0.0 4.8 11.8 0.0 Other 8.6 23.5
N 42 20 26 13 N 63 77 16 127
Central Gujarat Diclofenac 31.0 15.0 15.4 46.2 Madhya Pradesh Diclofenac 58.7 39.0 50.0 25.2
Meloxicam 45.2 60.0 57.7 15.4 Meloxicam 7.9 23.4 25.0 28.3
Nimesulide 11.9 15.0 15.4 7.7 Nimesulide 6.3 6.5 6.3 13.4
Piroxicam 2.4 0.0 0.0 0.0 Piroxicam 20.6 29.9 12.5 29.9
Other 9.5 10.0 11.5 30.8 Other 6.3 1.3 6.3 3.1
N 34 43 16 N 56
Southern Gujarat Diclofenac 11.8 7.0 37.5 Uttarakhand Diclofenac 51.8
Meloxicam 41.2 39.5 37.5 Meloxicam 16.1
Nimesulide 32.4 37.2 18.8 Nimesulide 5.4
Piroxicam 0.0 0.0 0.0 Piroxicam 17.9
Other 14.7 16.3 6.3 Other 8.9
N 33 83 N 50 11 89 32 59
Haryana pVSZ* Diclofenac 3.0 9.6 Uttar Pradesh Diclofenac 72.0 18.2 31.5 21.9 20.3
Meloxicam 69.7 43.4 Meloxicam 6.0 18.2 12.4 3.1 27.1
Nimesulide 18.2 37.3 Nimesulide 6.0 9.1 29.2 3.1 23.7
Piroxicam 0.0 2.4 Piroxicam 14.0 54.5 20.2 71.9 25.4
Other 9.1 7.2 Other       2.0 6.7 3.4
* Included neighbouring areas of Himachal Pradesh and Punjab                                                                                                                                                                                                                                  
** ‘Other’ NSAIDs include: aceclofenac, metamizole (Analgin), ketoprofen, mefenamic acid, phenylbutazone and tolfenamic acid                                                                                                                                    
*** A different method was used in surveys in 2012 and 2013 in Jharkhand, Uttarakhand and Uttar Pradesh (see Methods)





Table 2. Trends in the proportion of four NSAIDs offered for sale for use in cattle during covert (undercover) surveys of pharmacies in five regions of India 
between 2012 and 2017. 
(a) Diclofenac (b) Meloxicam
Region b SE t P b SE t P
Assam -0.471 0.20 2.39 0.018 0.112 0.14 0.82 0.41
Central Gujarat 0.109 0.14 0.81 0.42 -0.209 0.13 1.59 0.11
Southern Gujarat 0.374 0.15 2.55 0.012 -0.029 0.12 0.24 0.81
Madhya Pradesh -0.426 0.10 4.14 < 0.0001 0.348 0.12 2.83 0.005
Uttar Pradesh -0.306 0.20 1.55 0.12 0.509 0.23 2.19 0.03
(c) Nimesulide (d) Piroxicam
Region b SE t P b SE t P
Assam 0.406 0.24 1.70 0.09
Central Gujarat -0.058 0.19 0.30 0.76
Southern Gujarat -0.155 0.14 1.10 0.28
Madhya Pradesh 0.318 0.18 1.80 0.07 0.089 0.08 1.05 0.29
Uttar Pradesh -0.210 0.20 1.03 0.30 0.205 0.18 1.14 0.26





Table 3. The percentage of pharmacies that offered for sale six NSAIDs for use in cattle, during covert (undercover) surveys in various regions of Nepal, 2012-2017. N = the 
number of pharmacies that offered an NSAID.                                                                                                                                                                                                                                  
Year
Region NSAID 2012 2013 2014 2015 2016 2017
N 38 68





Tolfenamic acid 10.5 6.5
N 36 65 71
Western Pahad Diclofenac 0.0 0.0 0.0
Meloxicam 100 100 95.8
Nimesulide 0.0 0.0 2.8
Piroxicam 0.0 0.0 0.0
Ketoprofen 0.0 0.0 1.4
Tolfenamic acid 0.0 0.0 0.0
N 21 72 56 15 51
Western Terai Diclofenac 9.5 4.2 0.0 0.0 0.0
Meloxicam 90.5 95.8 98.2 100 84.3
Nimesulide 0.0 0.0 1.8 0.0 13.7
Piroxicam 0.0 0.0 0.0 0.0 0.0
Ketoprofen 0.0 0.0 0.0 0.0 0.0
Tolfenamic  acid 0.0 0.0 0.0 0.0 2.0
                                                                                                                                                                                                                                                                                                                                                                                                                     





Table 4. Trends in the proportion of diclofenac and meloxicam offered for sale for use in cattle during covert (undercover) surveys of ‘Animal’ pharmacies in 
three regions of Nepal, 2012-2017. Models for the Western Pahad region did not converge. Superscript ‘2’ denotes quadratic effect.
Diclofenac Meloxicam
Region b SE t P b SE t P
Eastern Terai -0.594 1.43 0.42 0.68 0.843 0.56 1.50 0.14















Table 5. The percentage (of all NSAIDs stocked) of seven NSAIDs available for use on cattle, during covert (undercover) surveys of pharmacies in three regions of 
Bangladesh, 2014-2018. N = the total number of NSAIDs stocked by pharmacies. The first survey covered the whole of the country.
      BANGLADESH Year
Region NSAID 2014 2015/16 2018
N 340




















Tolfenamic acid 3.4 5.4
Flunixin 0.6 1.6
Phenylbutazone 0.6 0






Figure 1. Percentage of pharmacies that offered for sale for use in cattle (a) diclofenac, (b) 
meloxicam and (c) nimesulide during covert (undercover) surveys of pharmacies in five regions of 
India from 2012 to 2017. Regression lines from predicted values fitted from logistic regression model 
included to illustrate trends in sales of NSAIDs in the five regions. Note varying scale of y-axis. 
Figure 2. Percentage of pharmacies that offered for sale for use in cattle (a) meloxicam, (b) 
diclofenac and (c) nimesulide during covert (undercover) surveys of pharmacies in three regions of 
Nepal from 2012 to 2017. Regression line from predicted values fitted from logistic regression model 
for the Western Terai region included to illustrate trends in sales of NSAIDs. No regression lines 
included for Eastern Terai, as only two surveys conducted. Models of trends in Western Pahad 
region did not converge. Note varying scale of y-axis.
Figure 3. Percentage of all NSAIDs stocked by pharmacies for use in cattle that were (a) ketoprofen, 
(b) meloxicam and (c) diclofenac during covert (undercover) surveys of pharmacies in Bangladesh 
from 2014 to 2018. The first survey covered the whole country, whereas later surveys were 
conducted in two provisional Vulture Safe Zones. Regression lines not included as regions only 
surveyed in 1-2 years. Note varying scale of y-axis.
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